HRS-7450
Unknown / undisclosed
Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.
Evidence outlook
Mid- and late-stage studies completed
This drug has completed mid- or late-stage studies. Where a sponsor has not posted registry results, topline data typically arrives via company announcements; see News.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (2)
What this study did
What this study did
Competitive landscape
This drug's own stage for Acute Ischemic Stroke: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| HRS-7450: this drug | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| Ticagrelor (Brilinta) | Approved | Small molecule | P2Y12 receptor | Reliable signal | NCT03354429: Composite of Subsequent Stroke or Death (From randomisation (day 1) to visit 3 (day 30-34)): TICAGRELOR 303 Participants | PLACEBO 362 Participants | |
| Edaravone (TTYP01) | Phase 3 | Small molecule | oxidative stress | not yet graded | No reviewed efficacy summary in this indication | |
| Rinvecalinase Alfa | Phase 2/3 | Protein / enzyme therapeutic | Tissue kallikrein-1 (KLK1) | not yet graded | No reviewed efficacy summary in this indication | |
| Apadamtase Alfa (Adzynma) | Phase 2 | Protein / enzyme therapeutic | ADAMTS13 | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-4029 | Phase 2 | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication | |
| HRS-8829 | —(overall) | Undisclosed | — | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
No upcoming readouts on record for this asset.